The Board Meeting was initially rescheduled on November 15, 2025 and thenafter on today i.e. November 17, 2025 hence Board has approved the Unaudited Financial statements for quarter and ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Parmax Pharma's board approved unaudited standalone results for Q2 and H1 FY26 (ended September 30, 2025) after a brief postponement from November 15. The company swung to a net profit of Rs 28.43 lakhs in H1 FY26, compared to a loss of Rs 20.21 lakhs in H1 FY25, helped by sharply lower reported expenses. Revenue from operations grew about 28% YoY to Rs 4.73 crore in H1 FY26. However, the balance sheet remains deeply stressed: shareholders' equity is negative at Rs -68.32 lakhs (worsened from Rs -19.89 lakhs at March-end 2025), and cash flow from operations turned sharply negative at Rs -33.35 lakhs. The auditor's limited review is unqualified but includes emphasis-of-matter notes regarding a pending Rs 3.5 crore insurance claim from a December 2023 fire and the company's decision not to charge depreciation on its cleanroom and effluent treatment plants.
While the headline return to profitability may look positive, shareholders should note that the company's net worth is eroded (negative equity), operating cash flow is bleeding, and the profit swing appears driven by unusually low expense bookings rather than strong core operations. The stock may face scrutiny over the depreciation policy and unresolved insurance claim, which together with rising borrowings (up to Rs 11.5 crore from Rs 7.7 crore) flag genuine going-concern risks.